0001562762-24-000071 | 10-K | XBRL Viewer

Print Document View Excel Document

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2023
Income Taxes [Abstract]
Income Taxes	12. Income Taxes The sources of losses from continuing operations, before income taxes, classified between domestic entities and those entities domiciled outside of the U.S., are as follows (in thousands): Years Ended December 31, Losses before taxes 2023 2022 Domestic entities $ (54,850) $ (69,745) Entities outside the U.S. (2,084) (5,477) $ (56,934) $ (75,222) Tax Rate Reconciliation The Company’s effective tax rate for the years ended December 31, 2023 and 2022 was 0.00 % and 0.00 %, respectively. A reconciliation of the provision for income taxes at the statutory rate to the amount reflected in the consolidated statements of operations is as follows (in thousands): Years Ended December 31, 2023 2022 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 2.29 % (1.17) % Stock compensation (1.08) % (0.68) % Foreign rate differential (0.31) % (0.59) % Uncertain tax positions 0.00 % 0.00 % Plane expense (1.15) % 0.00 % Other 0.67 % 1.41 % Change in valuation allowance (21.42) % ( 19.98 ) % Provision for income taxes 0.00 % 0.00 % Deferred Tax Assets (Liabilities) The Company computes income taxes using the liability method. This method requires recognition of deferred tax assets and liabilities, measured by enacted rates, attributable to temporary differences between the financial statements and the income tax basis of assets and liabilities. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that certain deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those specific jurisdictions prior to the dates on which such net operating losses expire. The Company maintained a full valuation allowance against its net deferred tax assets as of December 31, 2023 and 2022 because the Company has determined that it is more likely than not that these assets will not be fully realized based on a current evaluation of expected future taxable income and the Company is in a cumulative loss position. The valuation allowance increased by $ 12.2 million during the year ended December 31, 2023 and $ 15.0 million during the year ended December 31, 2022, primarily as a result of net operating losses generated during the periods. The Company reevaluates the positive and negative evidence at each reporting period. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 42,170 $ 39,184 Section 174 costs 15,631 7,424 Stock compensation 3,385 2,090 Other 225 559 Total deferred tax assets 61,411 49,257 Less: valuation allowance (61,369) (49,173) Net deferred tax assets $ 42 $ 84 Deferred tax liabilities: Depreciation $ (42) $ (84) Net deferred tax liabilities (42) (84) Net deferred income taxes $ — $ — Net Operating Losses As of December 31, 2023, the Company had total net operating loss carryforwards for U.S. federal income tax purposes of $ 178.8 million, of which $ 175.7 million have no expiration date, and foreign net operating loss carryforwards of $ 31.2 million that have no expiration date. Utilization of the NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code Sections 382 and 383 (the “Code”), as amended, and similar state provisions. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future. If the Company experienced an ownership change at any time since its formation, utilization of the NOL or tax credit carryforwards to offset future taxable income and taxes, respectively, would be subject to annual limitation under the Code. The annual limitation may result in the expiration of the NOL and credits before utilization. If impaired, the NOL and credit carryforwards would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Inflation Reduction Act (IRA) was signed into law on August 16, 2022. The IRA introduces a 15% corporate alternative minimum tax (CAMT) for corporations whose average annual adjusted financial statement income (AFSI) for any consecutive three-tax-year period ending after December 31, 2021 and preceding the tax year exceeds $1.0 billion and a 1% excise tax on stock repurchases made by publicly traded U.S. corporations. Since the Company does not meet the book income threshold to be subject to CAMT and the excise tax is not an ASC 740 tax, they are not expected to have any impact. The other tax law updates are not expected to have any material impact to the Company's consolidated financial statements and related disclosures. The CHIPS and Science Act was signed into law on August 9, 2022. The Act introduces the advanced manufacturing investment tax credit, a 25 % tax credit for investments in semiconductor manufacturing. It also includes incentives for manufacturing semiconductors, as well as specialized tooling equipment required in the semiconductor manufacturing process. The Company is not currently claiming any such tax credits, as such the tax law updates are not expected to have any material impact to the Company's consolidated financial statements and related disclosures. Enacted in 2017, the Tax Cuts and Jobs Act (“TCJA”) included significant changes in tax law including a change to Internal Revenue Code section 174 regarding the deductibility of research and experimentation expenses (“R&E expenses”). The section 174 tax law change had a delayed effective date and became effective for the Company in 2022. New section 174 requires that companies capitalize and amortize R&E expenses performed in the U.S. over five years and further provides for a fifteen-year amortization period for R&E expenses incurred outside the U.S. The Company has factored any impact of section 174 in the Company’s consolidated financial statements and related disclosures. The Company is subject to tax in the United States, many state and local, and foreign jurisdictions. The Company is currently not under audit in any US federal, state and local or foreign jurisdictions. Tax years starting from 2016 remain open to examination due to the carryover of unused net operating losses and tax credits. Uncertain Tax Positions A summary of the Company’s unrecognized tax benefits activity and related information is presented as follows (in thousands): Years Ended December 31, 2023 2022 Uncertain tax position liability at the beginning of the year $ 652 $ 652 Decreases during current period (617) — Uncertain tax position liability at the end of the year $ 35 $ 652 In 2023, $ 0.6 million of liabilities were reversed since the Company filed late returns for tax years 2016 and 2017 in October of 2020, and as such, the statute of limitations expired 3 years from that date, in October 2023.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Related Party Transactions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Research and development		$ 35,899	$ 47,627
United Biomedical Inc [Member]
Related Party Transaction [Line Items]
Warrants granted	1,928,020
Warrants, exercise price	$ 12.45
Warrant, contractual term	5 years
United Biomedical Inc [Member] \| UBI [Member]
Related Party Transaction [Line Items]
Percent of ownership		44.00%

Notes Payable (Tables)	12 Months Ended
Notes Payable (Tables)	Dec. 31, 2023
Note, 2025 [Member]
Debt Instrument [Line Items]
Carrying Values	December 31, 2023 2022 Principal $ 10,011 $ 10,455 Unamortized debt issuance cost (78) (131) Carrying amount 9,933 10,324 Less: current portion (406) (391) Note payable, net of current portion and debt issuance cost $ 9,527 $ 9,933
Schedule of Maturities of Notes Payable	Amount 2024 $ 458 2025 9,553 $ 10,011
2022 Promissory Note [Member]
Debt Instrument [Line Items]
Carrying Values	December 31, 2023 2022 Principal $ 3,112 $ 4,225 Less: current portion (1,029) (1,113) Note payable, net of current portion and debt issuance cost $ 2,083 $ 3,112
Schedule of Maturities of Notes Payable	Amount 2024 1,029 2025 1,103 2026 980 $ 3,112
2023 Promissory Note [Member]
Debt Instrument [Line Items]
Carrying Values	December 31, 2023 Principal $ 2,124 Less: current portion (472) Note payable, net of current portion $ 1,652
Schedule of Maturities of Notes Payable	Amount 2024 472 2025 517 2026 567 2027 568 $ 2,124

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,931	$ 33,475
Short-term investments	25,464	53,352
Restricted cash	105	1,095
Prepaid expenses and other current assets	2,316	5,551
Total current assets	33,230	93,887
Property and equipment, net	11,081	12,512
Total assets	44,311	106,399
Current liabilities:
Accrued expenses and other current liabilities	3,341	11,370
Total current liabilities	17,605	30,941
Other liabilities:
Other long-term liabilities	35	236
Total liabilities	30,902	44,222
Commitments and contingencies (Note 14)
Stockholders equity:
Additional paid-in capital	374,760	366,799
Accumulated other comprehensive income (loss)	8	(197)
Accumulated deficit	(361,637)	(304,703)
Total stockholders' equity	13,409	62,177
Total liabilities and stockholders' equity	44,311	106,399
Nonrelated Party [Member]
Current liabilities:
Accounts payable	1,783	5,295
Notes payable	406	391
Other liabilities:
Notes payable, net of current portion	9,527	9,933
Related Party [Member]
Current assets:
Amounts due	414	414
Current liabilities:
Accounts payable	10,575	12,772
Notes payable	1,500	1,113
Other liabilities:
Notes payable, net of current portion	3,735	3,112
Class A Common Stock [Member]
Stockholders equity:
Common stock, $0.0001 par value	278	278
Class B Common Stock [Member]
Stockholders equity:
Common stock, $0.0001 par value	$ 0	$ 0

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (56,934,000)	$ (75,222,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,234,000	1,684,000
Amortization of debt issuance costs	51,000	53,000
Amortization of discount on short-term investments	(1,554,000)	(1,022,000)
Stock-based compensation expense	7,508,000	8,714,000
Non-cash loss on disposal	0	43,000
Change in operating assets and liabilities:
Prepaid expenses and other current assets	3,236,000	3,300,000
Accrued expenses and other current liabilities	(8,029,000)	6,851,000
Other long-term liabilities	(201,000)	(1,000)
Net cash used in operating activities	(57,238,000)	(55,928,000)
Cash flows from investing activities:
Purchase of short-term investments	(63,942,000)	(107,526,000)
Redemption of short-term investments	93,589,000	55,000,000
Purchase of property and equipment	(803,000)	(1,866,000)
Net cash provided by (used in) investing activities	28,844,000	(54,392,000)
Cash flows from financing activities:
Repayment of notes payable	(444,000)	(430,000)
Repayments of note payable with related party	(1,150,000)	0
Proceeds from exercise of stock options	454,000	263,000
Net cash used in financing activities	(1,140,000)	(167,000)
Change in cash, cash equivalents, and restricted cash	(29,534,000)	(110,487,000)
Cash, cash equivalents and restricted cash at beginning of period	34,570,000	145,057,000
Cash, cash equivalents and restricted cash at end of period	5,036,000	34,570,000
Reconciliation of cash, cash equivalents and restricted cash:
Cash, cash equivalents and restricted cash at end of period	5,036,000	34,570,000
Less restricted cash	105,000	1,095,000
Cash and cash equivalents	4,931,000	33,475,000
Supplemental Disclosure
Cash paid for interest	799,000	367,000
Noncash Financing Activities
Conversion of amounts due to related party into note payable to related party	2,161,000	4,225,000
Nonrelated Party [Member]
Change in operating assets and liabilities:
Accounts payable	(3,512,000)	2,103,000
Related Party [Member]
Change in operating assets and liabilities:
Accounts receivable	(1,000)	(21,000)
Accounts payable	$ (36,000)	$ (2,410,000)

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued compensation	$ 1,558,000	$ 2,568,000
Accrued external research and development	1,202,000	6,904,000
Accrued professional fees and other	560,000	1,722,000
Accrued interest	21,000	176,000
Total	$ 3,341,000	$ 11,370,000

Net Loss Per Share	12 Months Ended
Net Loss Per Share	Dec. 31, 2023
Net Loss Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The Company’s potentially dilutive securities, which include options, unvested restricted stock, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 because including them would have had an anti-dilutive effect: December 31, 2023 2022 Unvested restricted stock 200,000 300,000 Options issued and outstanding 21,923,762 20,416,760 Warrants issued and outstanding 1,928,020 1,928,020 24,051,782 22,644,780

Commitments and Contingencies (Narrative) (Details)		1 Months Ended		3 Months Ended	12 Months Ended
Commitments and Contingencies (Narrative) (Details)	Nov. 03, 2021 USD ($)	Apr. 30, 2022 USD ($) ft²	Aug. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) Item shares	Dec. 31, 2022 USD ($)	Aug. 31, 2023 USD ($) ft²	Apr. 30, 2021 USD ($)
Commitments And Contingencies [Line Items]
Rent expense					$ 600,000	$ 500,000
Shares issued \| shares					32,505,306
Number of Operating Lease Agreements \| Item					2
Materials Expensed				$ 0
Florida Lease [Member]
Commitments And Contingencies [Line Items]
Area Of Land \| ft²							9,839
Security deposit							$ 100,000
Lease, initial term							1 year
Lease obligation							$ 500,000
New York Lease [Member]
Commitments And Contingencies [Line Items]
Area Of Land \| ft²		4,419
Lease, initial term		1 year
Indemnification Agreement [Member]
Commitments And Contingencies [Line Items]
Purchase obligation				$ 0	$ 0	0
Expected Claim [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Potential loss					4,200,000
Expected Claim [Member] \| Minimum [Member]
Commitments And Contingencies [Line Items]
Potential loss					0
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments					0
UB-612 [Member]
Commitments And Contingencies [Line Items]
Materials Ordered			$ 7,200,000
Materials Ordered And Paid			3,000,000.0
Materials Expensed					3,000,000.0
Materials Received			3,000,000.0
Amount of material canceled			$ 4,200,000
Purchase obligation								$ 3,000,000
Michael J Fox Foundation Grant [Member]
Commitments And Contingencies [Line Items]
Reduction In Research And Development					0	100,000
Project Grant	$ 800,000
Grant, Accrued Liability, Current					0
Coalition For Epidemic Preparedness Innovations Cepi Grant [Member]
Commitments And Contingencies [Line Items]
Restricted Cash And Current Accrued Liability					0
Reduction In Research And Development					$ 1,800,000	$ 7,500,000
Project Grant		$ 9,300,000

Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Net operating loss carryforwards	$ 42,170	$ 39,184
Section 174 Costs	15,631	7,424
Stock Compensation	3,385	2,090
Other	225	559
Total deferred tax assets	61,411	49,257
Less: valuation allowance	(61,369)	(49,173)
Net deferred tax assets	42	84
Depreciation	(42)	(84)
Net deferred tax liabilities	(42)	(84)
Net deferred income taxes	$ 0	$ 0

Short Term Investments	12 Months Ended
Short Term Investments	Dec. 31, 2023
Short Term Investments [Abstract]
Short Term Investments	3. Short Term Investments The Company’s short-term investments consist of the following (in thousands): As of December 31, 2023 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 25,456 $ 8 $ 25,464 Total $ 25,456 $ 8 $ 25,464 As of December 31, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 53,549 $ (197) $ 53,352 Total $ 53,549 $ (197) $ 53,352

Notes payable (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Notes payable (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Oct. 31, 2022	Jun. 30, 2020
Note 2025 [Member]
Debt Instrument [Line Items]
Notes payable			$ 4.2	$ 11.5
Debt Instrument Interest Rate Stated Percentage				3.40%
Debt maturity date				Jun. 09, 2025
Interest Expense, Debt	$ 0.4	$ 0.4
Debt Instrument Periodic Payment Interest	0.1
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid	9.4
Payments Of Debt Issuance Costs	0.3
Promissory 2022 Note [Member]
Debt Instrument [Line Items]
Notes payable			$ 4.2
Debt Instrument Interest Rate Stated Percentage			7.00%
Interest Expense, Debt	0.2	$ 0.1
Promissory 2023 Note [Member]
Debt Instrument [Line Items]
Notes payable	$ 2.2
Debt Instrument Interest Rate Stated Percentage	9.25%
Debt maturity date	Nov. 01, 2027
Interest Expense, Debt	$ 0.1

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Dec. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Options issued and outstanding	21,923,762	20,416,760
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding	22,123,762	20,716,760
Options available for future grants	6,266,663	6,064,003
Warrants issued and outstanding	1,928,020	1,928,020
Reserved Shares of Common Stock	30,318,445	28,708,783

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

+ Details

Net Loss Per Share (Tables)	12 Months Ended
Net Loss Per Share (Tables)	Dec. 31, 2023
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	December 31, 2023 2022 Unvested restricted stock 200,000 300,000 Options issued and outstanding 21,923,762 20,416,760 Warrants issued and outstanding 1,928,020 1,928,020 24,051,782 22,644,780

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2023
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 25,464 $ — $ — $ 25,464 Money market account 1,029 — — 1,029 Total assets $ 26,493 $ — $ — $ 26,493 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 53,352 $ — $ — $ 53,352 Money market account 27,724 — — 27,724 Total assets $ 81,076 $ — $ — $ 81,076

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 25,464,000	$ 53,352,000
Cash and cash equivalents	4,931,000	33,475,000
Assets	26,493,000	81,076,000
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,029,000	27,724,000
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	25,464,000	53,352,000
Assets	26,493,000	81,076,000
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,029,000	27,724,000
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Assets	0	0
Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Assets	0	0
Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 0	$ 0

Summary of Significant Accounting Policies (Policy)	12 Months Ended
Summary of Significant Accounting Policies (Policy)	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial reporting.
Foreign currency translation	Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Statement of operations accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency translation (gains) losses in the consolidated statements of operations.
Segment information	Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment.
Use of estimates	Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of stock-based compensation, prepaid expense recognition, income tax valuation allowance and accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions.
Related party transactions	Related party transactions The Company has a policy governing related party transactions that defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Audit Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Audit Committee determines in good faith that the transaction is consistent with the interests of the Company and its shareholders.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return.
Restricted cash	Restricted cash As of December 31, 2023 and 2022 a deposit of $ 0.1 million and $ 1.1 million, respectively, was restricted from withdrawal. These restrictions related to securing credit card obligations as of December 31, 2023, and cash payments received in advance under the CEPI Funding Agreement and securing credit card obligations as of December 31, 2022. These balances are included in restricted cash on the accompanying consolidated balance sheets.
Short term investments	Short Term Investments The Company determines the appropriate classification of its investments at the time of purchase. Currently, all of the Company’s investments are classified as available-for-sale in accordance with ASC Topic 320, Investments – Debt Securities (“ASC 320”). The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income or loss. Realized gains and losses, interest income earned on the Company’s cash, cash equivalents and investments, and amortization or accretion of discounts and premiums on investments are included within other income (expense) on the accompanying consolidated statements of operations and other comprehensive loss. Available-for-sale debt securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported within equity as accumulated other comprehensive income (loss) on the accompanying consolidated statements of stockholder’s equity. The Company did no t record any such impairments during the years ended December 31, 2023 and 2022.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers.
Leases	Leases At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating or financing. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in our consolidated balance sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. The Company has elected to apply the practical short-term expedient to leases with a lease term of 12 months or less, which does not subject the leases to capitalization.
Property and equipment	Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term
Impairment of long-lived assets	Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets.
Deferred offering costs	Deferred offering costs The Company capitalizes certain legal, audit, accounting and other third-party fees that are directly associated with an in-process capital financing effort as deferred offering costs until such financing is consummated. After consummation of the financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the financing. Should the financing be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the accompanying consolidated statements of operations and other comprehensive loss. The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statements of operations and other comprehensive loss.
Fair value measurements	Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Coalition for epidemic preparedness ("CEPI") grant	Coalition for Epidemic Preparedness (“CEPI”) grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID- 19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in early 2022, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. Cash payments received in advance under the CEPI Funding Agreement were restricted as to their use until expenditures contemplated in the funding agreement were incurred. As funds were received they were included within restricted cash offset by a corresponding short-term accrued liability. The Company recognized payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant was intended to reimburse were incurred.
Research and development	Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 16). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent costs	Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-based compensation	Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and other comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model (“Black-Scholes”), which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. The Company, both prior to and after the IPO in November 2021, lacks sufficient company-specific historical and implied volatility information for its stock, and therefore estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The conditions present in the Company's grants contain both performance and market conditions. The effect of each market condition is reflected in the grant-date fair value and the performance-based options are recognized considering the probability of satisfying the performance and market conditions. The Company has used a Monte Carlo Simulation Model to calculate the fair value of the grant considering the market condition (the 25% higher value after the IPO condition). The performance condition was determined to not be probable at the time of the grant date, and the recognition of compensation cost was deferred until the IPO was consummated in November 2021. The recognition of expense for the portion of the grant-date fair value assigned to the market condition has been recognized as expense according to the derived service period in the valuation model.
Income taxes	Income taxes The Company accounts for income taxes according to the ASC 740, Income Taxes (“ASC 740”) using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax positions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net loss per share	Net loss per share Basic earnings per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. For purpose of this calculation, outstanding options, unvested restricted stock and warrants are considered potential dilutive common stock and are excluded from the computation of net loss per share if their effect is anti-dilutive.
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, as long as the Company remains an EGC, it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs.
Recently adopted accounting standards	Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018- 11provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company did not enter into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	4. Fair Value Measurements The fair values of our cash and certain cash equivalents, accounts payable, and other current assets and current liabilities approximate their carrying values due to their short-term maturities. The Company's money market accounts and short-term investments are shown at fair value based on unadjusted quoted market prices in active markets for identical assets. The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): During the years ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3. December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 25,464 $ — $ — $ 25,464 Money market account 1,029 — — 1,029 Total assets $ 26,493 $ — $ — $ 26,493 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ 53,352 $ — $ — $ 53,352 Money market account 27,724 — — 27,724 Total assets $ 81,076 $ — $ — $ 81,076

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Useful Life of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2023
Airplane [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	Shorter of the useful life of improvement or the remaining lease term

Common Stock (Narrative) (Details) - $ / shares	12 Months Ended
Common Stock (Narrative) (Details) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Issuance of stock, shares	32,505,306
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,100,000,000
Common stock, par value	$ 0.0001
Amended And Restated Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,000,000,000
Amended And Restated Common Stock [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Property and Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation	$ 2,234	$ 1,684

Notes payable (Annual Principal Payments) (Details) - Notes Payable [Member] - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Note, 2025 [Member]
Debt Instrument [Line Items]
2024	$ 458,000
2025	9,553,000
2026	9,553,000
Total	10,011,000	$ 10,455,000
Promissory 2022 Note [Member]
Debt Instrument [Line Items]
2024	1,029,000
2025	1,103,000
2026	980,000
Total	3,112,000	$ 4,225,000
Promissory 2023 Note [Member]
Debt Instrument [Line Items]
2024	472,000
2025	517,000
2026	567,000
2027	568,000
Total	$ 2,124,000

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events On March 8, 2024, a Special Committee (the “Committee”) of the Board of Directors of Vaxxinity, Inc. approved an option repricing (the “Repricing”). The Repricing generally applied to continuing employees and officers with (a) underwater options to purchase shares of the Company’s Class A common stock that were granted to employees (such options, the “Employee Options”) and to Louis Reese, the Company’s Executive Chairman, and Mei Mei Hu, the Company’s Chief Executive Officer (together with Mr. Reese, the “Founders”) under the Company’s Omnibus Plan and the 2021 Pre-IPO Plan and (b) underwater options to purchase shares of the Company’s Class B common stock granted pursuant to stock option agreements governed by the terms of the 2021 Pre-IPO Plan (together with the Employee Options, the “Eligible Options”). The total number of shares of Class A and Class B common stock underlying all Eligible Options was approximately 10,105,140 shares. The Eligible Options were repriced such that the exercise price per share for such options was reduced to $ 0.70 , the closing price of the Company’s Class A common stock on the Nasdaq Global Market on March 8, 2024, the most recent closing price of the Company’s Class A common stock prior to the Repricing. In order to exercise the Employee Options at the reduced exercise price, holders are required to remain in service with the Company (or otherwise be eligible to exercise their options pursuant to any applicable post-termination exercise period) through the end of a “Retention Period” that ends on the earlier of: (a) December 31, 2024 and (b) a Change of Control, as defined in the Omnibus Plan. If an employee exercises an Employee Option prior to the end of the Retention Period, such employee will be required to pay a premium exercise price equal to the original exercise price per share of such Employee Option. Options subject to the Repricing held by the Founders will be exercisable in accordance with their terms, and shares of Class B common stock acquired upon exercise of such options will be subject to a lock-up restriction prohibiting sales for a period of two years from the Repricing Date. In addition, the Founders will not be eligible to receive annual equity grants in 2024 and 2025. The Company is evaluating the impact of the Repricing and will disclose this impact in its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024.

Income Taxes (Reconciliation of Income Tax Percent) (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Income taxes at statutory rate	21.00%	21.00%
State and local taxes, net of federal benefits	2.29%	(1.17%)
Stock compensation	(1.08%)	(0.68%)
Foreign rate differential	(0.31%)	(0.59%)
Uncertain tax positions	0.00%	0.00%
Plane Expense	(1.15%)	0.00%
Other	0.67%	1.4125%
Change in valuation allowance	(21.42%)	(19.975%)
Provision for income taxes	0.00%	0.00%

Nature of the Business	12 Months Ended
Nature of the Business	Dec. 31, 2023
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, Inc., a Delaware corporation (“Vaxxinity ,” and together with its subsidiaries, the “Company”), was formed through the combination of two separate businesses that originated from United Biomedical, Inc. (“UBI”) in two separate transactions: a spin-out from UBI in 2014 of operations focused on developing chronic disease product candidates that resulted in United Neuroscience (“UNS”), and a second spin-out from UBI in 2020 of operations focused on the development of a COVID-19 vaccine that resulted in C19 Corp. (“COVAXX”). On February 2, 2021, Vaxxinity was incorporated for the purpose of reorganizing and combining UNS and COVAXX and on March 2, 2021, did so by acquiring all of the outstanding equity interests of UNS and COVAXX pursuant to a contribution and exchange agreement (the “Contribution and Exchange Agreement”) whereby the existing equity holders of UNS and COVAXX contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity (the “Reorganization”). The Company is a biotechnology company currently focused on developing product candidates for human use in the fields of neurology, pain, cardiovascular diseases and coronaviruses utilizing its “Vaxxine Platform”—a synthetic peptide vaccine technology first developed by UBI and subsequently refined over the last two decades. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic diseases with large global unmet medical need. The Company is also developing a heterologous booster vaccine for SARS-Cov-2. UBI is a significant shareholder of the Company and, therefore, considered a related party. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company’s product candidates are in development and will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees and consultants. Liquidity and Going Concern Assessment As of December 31, 2023, the Company had $ 4.9 million of cash and cash equivalents and $ 25.5 million of short-term investments to fund operations. To date, the Company has primarily financed its operations through the sale of convertible preferred stock and common stock, borrowings under promissory notes (including Convertible Notes), a portion of which has been raised from related party entities, and grants from foundations such as the Coalition of Epidemic Preparedness Innovations (CEPI) and the Michael J. Fox Foundation (MJFF). The Company has experienced significant negative cash flows from operations since inception, and incurred a net loss of $ 56.9 million for the year ended December 31, 2023. Net cash used in operating activities for the year ended December 31, 2023 was $ 57.2 million. In addition, as of December 31, 2023, the Company has an accumulated deficit of $ 361.6 million. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. In accordance with ASC 205-40, Presentation of Financial Statements-Going Concern, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. When management identifies conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern, management must consider whether its plans to mitigate those relevant conditions or events will alleviate the substantial doubt. Given that the Company has incurred substantial operating losses and negative cash flows from operations since inception and expects to continue to incur substantial operating losses and negative cash flows from operations for the foreseeable future, management assessed that there are conditions or events, considered in the aggregate, as of the issue date of these financial statements, which raise substantial doubt about the Company's ability to continue as a going concern. Management considered whether its plans to mitigate those relevant conditions or events will alleviate the substantial doubt about the Company’s ability to continue as a going concern. These plans include raising new capital through public or private equity offerings, strategic collaborations, debt financing and other capital sources or combinations thereof, and as needed cost reduction through attrition, organization restructuring, and curtailment of certain research and development activities. However, there are significant risks and uncertainties as to whether these plans will be achieved or additional funding will be available on terms acceptable to the Company, or at all. Due to the risks and uncertainties, management cannot conclude that substantial doubt about the Company's ability to continue as a going concern has been alleviated. As such, there is substantial doubt about the entity's ability to continue as a going concern within one year after the date that these financial statements are issued. However, since liquidation is not imminent, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Insurance	$ 1,235	$ 1,870
Deposits	241	232
Clinical prepayments	0	2,679
Prepaid materials and supplies	0	248
Other	840	522
Total	$ 2,316	$ 5,551

Equity Incentive Plan (Weighted Average Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	3.46%	1.46%
Risk-free interest rate, maximum	5.58%	4.22%
Expected volatility, minimum	47.64%	90.01%
Expected volatility, maximum	83.09%	97.82%
Expected dividend yield	0.00%	0.00%
Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.58%	0.58%
Expected term (in years)	4 years 6 months
Expected volatility	0.75%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 10.07
Peter Diamandis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.0009%
Expected term (in years)	1 year
Expected volatility	0.90%
Cost Of Equity	0.25%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 4.12
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	1 month 13 days	5 years 6 months
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 9 days	6 years 1 month 6 days

Equity Incentive Plan (Narrative) (Details - USD ($)		1 Months Ended	12 Months Ended
Equity Incentive Plan (Narrative) (Details - USD ($)	Jan. 01, 2024	Aug. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding			21,923,762	20,416,760
Options exercisable			16,452,984
Total stock-based compensation expense			$ 7,508,000	$ 8,714,000
Shares canceled			2,376,905
Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate			0.58%	0.58%
Scenario Previously Reported [Member] \| Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate				58.00%
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant			6,266,663	6,064,003
Options outstanding			22,123,762	20,716,760
Minimum [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period			1 year
Employee and Non-Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period			4 years
Employee and Non-Employees [Member] \| Performance And Market Based [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding			5,983,670
Class A Common Stock [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding			15,561,307
Options exercisable			11,389,851
Common Class B [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding			6,362,455
Options exercisable			5,063,133
2021 Stock Option and Grant Plan [Member] \| First Anniversary [Member] \| Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested			$ 0
2021 Stock Option and Grant Plan [Member] \| Performance And Market Based [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant					6,799,625
Shares vested					5,439,700
2021 Stock Option and Grant Plan [Member] \| Board of Directors [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable			815,955
Intrinsic value of options exercised			$ 300,000
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan			21,593,830
Omnibus Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price threshold as a percentage of combined voting power			10.00%
Minimum exercise price for grantees under combined voting power threshold			100.00%
Minimum exercise price for grantees under combined voting power threshold			110.00%
Award expiration term			10 years
Award expiration term for grantees under combined voting power threshold			5 years
Total unrecognized compensation cost			$ 8,000,000.0
Recognized over a weighted average period			2 years 2 months 12 days
Omnibus Plan [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options exercised			$ 200,000	$ 4,500,000
Weighted-average grant-date fair value per share of options granted			$ 1.41	$ 2.21
Total fair value of options vested			$ 9,200,000	$ 8,800,000
Omnibus Plan [Member] \| Class A Common Stock [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan						8,700,000
Increase in number of shares available for grant	16,401,213
Number of shares available for grant			6,266,663
Percentage increase in shares available for grant						4.00%
Omnibus Plan [Member] \| Class A Common Stock [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable					6,799,625
Omnibus Plan [Member] \| Common Class B [Member] \| Employee and Non-Employees [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding		5,983,670
Total fair value of options vested		$ 23,800,000

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2023
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): Prepaid insurance consists primarily of $ 1.2 million and $ 1.6 million for the unamortized portion of the Company’s annual D&O insurance premiums as of December 31, 2023 and 2022, respectively. Deposits consist of amounts held by the Company’s travel and logistics company and the leaseholder for the Florida lab. Clinical prepayments consist of amounts paid in advance to clinical research organizations (“CROs”) for expenses related to our clinical trials, primarily UB-612, that are amortized to expense as earned by the CRO and clinical trial sites. Prepaid materials and supplies consist of amounts paid in advance related to the procurement and/or production of materials for use in the Company’s clinical trials, primarily UB-612. Other prepaid expenses and current assets consist primarily of prepaid expenses incurred in the normal course of business, including software subscriptions and prepaid maintenance. Costs related to the establishment of the Company’s at-the-market offering program during 2023 were recorded as prepaid expense and will be charged against equity raised under the program. As of December 31, 2023, no shares have been sold under the program. December 31, 2023 2022 Prepaid insurance $ 1,235 $ 1,870 Deposits 241 232 Clinical prepayments — 2,679 Prepaid materials and supplies — 248 Other 840 522 $ 2,316 $ 5,551

Equity Incentive Plans (Tables)	12 Months Ended
Equity Incentive Plans (Tables)	Dec. 31, 2023
Equity Incentive Plan [Abstract]
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2022 20,416,760 $ 5.07 6.8 $ 7,166 Granted 4,573,829 2.02 Exercised (689,922) 0.66 Forfeited (2,376,905) 6.55 Balance at December 31, 2023 21,923,762 $ 4.42 6.0 $ 3,158 Options vested and exercisable at December 31, 2023 16,452,984 $ 4.37 5.6 $ 3,155
Weighted Average Assumptions	December 31, 2023 2022 Risk-free interest rate 3.46 % - 5.58 % 1.46 % - 4.22 % Expected term (in years) 0.12 - 6.11 5.5 - 6.1 Expected volatility 47.64 % - 83.09 % 90.01 % - 97.82 % Expected dividend yield 0.00 % 0.00 % Time to expiration (in years) 4.5 Volatility 75% Risk-free interest rate 0.58% Cost of equity 25% Fair value of underlying common stock (as of valuation date) $10.07 Time to expiration (in years) 1 Volatility 90% Risk-free interest rate 0.09% Cost of equity 25% Fair value of underlying common stock (as of valuation date) $4.12
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2022 300,000 $ 3.76 Issued — — Forfeited (100,000) 3.76 Unvested at December 31, 2023 200,000 $ 3.76
Schedule of Stock-Based Compensation Expense for Stock Options	Years Ended December 31, 2023 2022 Research and development $ 2,565 $ 3,276 General and administrative 4,943 5,438 Total stock-based compensation expense $ 7,508 $ 8,714

Other Long-Term Liabilities (Tables)	12 Months Ended
Other Long-Term Liabilities (Tables)	Dec. 31, 2023
Other Long-Term Liabilities [Abstract]
Other Liabilities	December 31, 2023 2022 Accrued tax provision $ 35 $ 236 $ 35 $ 236

Property and Equipment, Net (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment	$ 16,948	$ 16,136
Less: accumulated depreciation	(5,867)	(3,624)
Property and equipment, net	11,081	12,512
Airplane [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	3,649	3,146
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	576	403
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	426	415
Facilities, Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	99	37
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	87	87
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 128	$ 65

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2023
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	December 31, 2023 2022 Options and RSUs issued and outstanding 22,123,762 20,716,760 Options available for future grants 6,266,663 6,064,003 Warrants issued and outstanding 1,928,020 1,928,020 30,318,445 28,708,783

Equity Incentive Plan	12 Months Ended
Equity Incentive Plan	Dec. 31, 2023
Equity Incentive Plan [Abstract]
Equity Incentive Plan	11. Equity Incentive Plan Stock Options In March 2021, the Company replaced the 2017 and 2020 Stock Option and Grant Plans with the 2021 Stock Option and Grant Plan (the “2021 Pre-IPO Plan”), which provided for the Company to grant qualified incentive options, nonqualified options, restricted stock awards, unrestricted stock awards, and restricted stock units to employees and non-employees to purchase the Company’s Class A common stock. The 2021 Pre-IPO Plan authorized the issuance of up to 21,593,830 shares of Class A common stock pursuant to awards. In November 2021, our stockholders approved replacing the 2021 Pre-IPO Plan with the 2021 Omnibus Incentive Compensation Plan (the “Omnibus Plan”), which provides for the Company to grant nonqualified stock options, incentive (qualified) stock options, stock appreciation rights, restricted share awards, restricted stock units, performance awards, cash incentive awards and other equity-based awards (including fully vested shares). The Omnibus Plan replaced the 2021 Pre-IPO Plan and no further grants will be made under the 2021 Pre-IPO Plan. The following is a summary of certain terms and conditions of the Omnibus Plan. At its inception in November 2021, the maximum number of shares of common stock that could be issued under the Omnibus Plan was 8,700,000 shares of Class A equity. This number increases automatically on January 1 of each year, commencing January 1, 2023, by the number of shares equal to the lesser of (i) 4 % of the outstanding shares of the Company’s common stock on the immediately preceding December 31, (ii) the number of shares determined by the Compensation Committee, if any such determination is made, and (iii) the number of shares underlying any awards granted during the preceding calendar year, net of the shares underlying awards canceled or forfeited under the Omnibus Plan. On January 1, 2024, in accordance with the automatic “evergreen” provision of the Omnibus Plan, the maximum number of shares that can be issued under the plan was increased to 16,401,213 . As of December 31, 2023, 6,266,663 shares were available for future grant. Shares issued under the Omnibus Plan that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of stock, withheld to cover the exercise price or tax withholdings, or otherwise terminated, other than by exercise, shall be added back to the shares available for issuance under the Omnibus Plan. The exercise price for grants made pursuant to the terms of the Omnibus Plan is determined in the applicable grant by the board of directors. Any incentive options granted to persons possessing less than 10 % of the total combined voting power of all classes of stock may not have an exercise price of less than 100 % of the fair market value of the common stock on the grant date. Any incentive options granted to persons possessing more than 10 % of the total combined voting power of all classes of stock may not have an exercise price of less than 110 % of the fair market value of the common stock on the grant date. The option term for incentive awards may not be greater than ten years from the date of the grant. Incentive options granted to persons possessing more than 10 % of the total combined voting power of all classes of stock may not have an option term of greater than five years from the date of the grant. The vesting period for equity-based awards is determined at the discretion of the board of directors. As of December 31, 2023 there were options to purchase 15,561,307 shares of Class A common stock outstanding and options to purchase 6,362,455 shares of Class B common stock outstanding, of which 11,389,851 Class A and 5,063,133 Class B shares, respectively were exercisable. Stock Option Activity The following table summarizes stock option activity for the year ended December 31, 2023: The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock. The intrinsic value of options exercised during each of the years ended December 31, 2023 and 2022 was $ 0.2 million and $ 4.5 million, respectively. The weighted-average grant-date fair value per share of options granted during the years ended December 31, 2023 and 2022 was $ 1.41 and $ 2.21 , respectively. The total fair value of options vested during the years ended December 31, 2023 and 2022 was $ 9.2 million and $ 8.8 million, respectively. Valuation of Stock Options Granted that Contain Service Conditions Only The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the assumptions noted in the table below for those options granted in the years ended December 31, 2023 and 2022: Stock Options Granted to Employees that Contain Performance and Market Conditions Included in the stock options granted during the year ended December 31, 2021 were stock options to purchase 6,799,625 shares of Class A common stock that contain performance- and market-based vesting conditions granted to the Mei Mei Hu, Louis Reese, and Peter Diamandis. As of December 31, 2023, 5,983,670 options with performance- and market-based vesting conditions remain outstanding. The rest have either been exercised or expired. In August 2021, the stock option awards for the Mei Mei Hu and Louis Reese totaling 5,983,670 shares were cancelled in exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. The fair value of the awards granted to Mei Mei Hu and Louis Reese at the modification date was $ 23.8 million, valued using the Monte-Carlo simulation model. The assumptions used in the Monte-Carlo simulation model were as follows: In connection with preparing its financial statements for the fiscal year ended December 31, 2023, the Company identified an error with how the risk-free interest rate was reported in the financial statements for the fiscal year ended December 31, 2022. The risk-free interest rate was reported as 58.00 % when it should have been reported as 0.58 %. This error has been corrected in the table above. The stock option awards for Peter Diamandis totaling 815,955 shares had a grant date fair value of $ 0.3 million. The assumptions used in the Monte-Carlo simulation model were as follows: The compensation expense for these awards is recognized when the vesting condition is met for the performance-based criteria, and over the derived service period for the market-based criteria. The condition for the performance-based criteria in the stock options was based on the Company's completion of its IPO, and the condition for the market-based criteria in the stock options was based on the future price of the Company's common stock trading at or above a specified threshold. During the year ended December 31, 2021, stock options for an aggregate of 5,439,700 shares of the total 6,799,625 shares containing performance- and market-based vesting conditions were vested following the satisfaction of the performance-based condition achieved through the Company’s completion of its IPO. As of December 31, 2023, the market-based vesting conditions had not been achieved. Restricted Stock The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2023: No restricted stock vested during the years ended December 31, 2023 and 2022. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations (in thousands): As of December 31, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $ 8.0 million, which is expected to be recognized over a weighted average period of 2.2 years. Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2022 20,416,760 $ 5.07 6.8 $ 7,166 Granted 4,573,829 2.02 Exercised (689,922) 0.66 Forfeited (2,376,905) 6.55 Balance at December 31, 2023 21,923,762 $ 4.42 6.0 $ 3,158 Options vested and exercisable at December 31, 2023 16,452,984 $ 4.37 5.6 $ 3,155 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2022 300,000 $ 3.76 Issued — — Forfeited (100,000) 3.76 Unvested at December 31, 2023 200,000 $ 3.76 Years Ended December 31, 2023 2022 Research and development $ 2,565 $ 3,276 General and administrative 4,943 5,438 Total stock-based compensation expense $ 7,508 $ 8,714 December 31, 2023 2022 Risk-free interest rate 3.46 % - 5.58 % 1.46 % - 4.22 % Expected term (in years) 0.12 - 6.11 5.5 - 6.1 Expected volatility 47.64 % - 83.09 % 90.01 % - 97.82 % Expected dividend yield 0.00 % 0.00 % Time to expiration (in years) 4.5 Volatility 75% Risk-free interest rate 0.58% Cost of equity 25% Fair value of underlying common stock (as of valuation date) $10.07 Time to expiration (in years) 1 Volatility 90% Risk-free interest rate 0.09% Cost of equity 25% Fair value of underlying common stock (as of valuation date) $4.12

Equity Incentive Plan (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 7,508	$ 8,714
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,565	3,276
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 4,943	$ 5,438

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2021	$ 128,619,000			$ 278,000	$ 0	$ 357,822,000	$ 0	$ (229,481,000)
Beginning balance, common shares at Dec. 31, 2021				111,518,094	13,874,132
Issuance of common stock upon exercise of stock options, shares				664,656
Issuance of common stock upon exercise of stock options	263,000			$ 0		263,000
Stock-based compensation expense	8,714,000					8,714,000
Unrealized gain (loss) on investments	(197,000)						(197,000)
Net loss	(75,222,000)							(75,222,000)
Ending balance at Dec. 31, 2022	$ 62,177,000			$ 278,000	$ 0	366,799,000	(197,000)	(304,703,000)
Ending balance, common shares at Dec. 31, 2022		112,182,750	13,874,132	112,182,750	13,874,132
Issuance of common stock upon exercise of stock options, shares	689,922			689,922
Issuance of common stock upon exercise of stock options	$ 453,000					454,000
Stock-based compensation expense	7,508,000					7,508,000
Unrealized gain (loss) on investments	205,000						205,000
Net loss	(56,934,000)							(56,934,000)
Ending balance at Dec. 31, 2023	$ 13,409,000			$ 278,000	$ 0	$ 374,761,000	$ 8,000	$ (361,637,000)
Ending balance, common shares at Dec. 31, 2023		112,872,672	13,874,132	112,872,672	13,874,132

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

Equity Incentive Plan (Summary of Restricted Stock Activity) (Details) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested at December 31, 2022 \| shares	300,000
Number of Shares, Issued \| shares	100,000
Number of Shares, Unvested at December 31, 2023 \| shares	200,000
Weighted Average Grant Date Fair Value Per Share, Unvested at December 31, 2022 \| $ / shares	$ 3.76
Weighted Average Grant Date Fair Value Per Share, Issued \| $ / shares	3.76
Weighted Average Grant Date Fair Value Per Share, Unvested at December 31, 2023 \| $ / shares	$ 3.76

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]
Transfer amount between classes	$ 0	$ 0

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2023
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	December 31, 2023 2022 Prepaid insurance $ 1,235 $ 1,870 Deposits 241 232 Clinical prepayments — 2,679 Prepaid materials and supplies — 248 Other 840 522 $ 2,316 $ 5,551

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2023
Property and Equipment, Net [Abstract]
Property and Equipment, Net	December 31, 2023 2022 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 3,649 3,146 Leasehold improvements 576 403 Software 426 415 Facilities, furniture and fixtures 99 37 Vehicles 87 87 Construction in progress 128 65 Total property and equipment 16,948 16,136 Less: accumulated depreciation (5,867) (3,624) $ 11,081 $ 12,512

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term 2. Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial reporting. Foreign currency translation The Company’s consolidated financial statements are prepared in U.S. dollars. Its foreign subsidiaries use the U.S. dollar as their functional currency and maintain their records in the local currency. Nonmonetary assets and liabilities are re-measured at historical rates and monetary assets and liabilities are re-measured at exchange rates in effect at the end of the reporting period. Statement of operations accounts are re-measured at average exchange rates for the reporting period. The resulting gains or losses are included in foreign currency translation (gains) losses in the consolidated statements of operations. Segment information Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates as a single operating segment and has one reportable segment. Use of estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these consolidated financial statements include, but are not limited to, the estimated fair value of stock-based compensation, prepaid expense recognition, income tax valuation allowance and accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions. Related party transactions The Company has a policy governing related party transactions that defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Audit Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Audit Committee determines in good faith that the transaction is consistent with the interests of the Company and its shareholders. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents, including balances held in the Company’s money market accounts. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company’s cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company’s cash flow requirements, and to attain a market rate of return. Restricted cash As of December 31, 2023 and 2022 a deposit of $ 0.1 million and $ 1.1 million, respectively, was restricted from withdrawal. These restrictions related to securing credit card obligations as of December 31, 2023, and cash payments received in advance under the CEPI Funding Agreement and securing credit card obligations as of December 31, 2022. These balances are included in restricted cash on the accompanying consolidated balance sheets. Short Term Investments The Company determines the appropriate classification of its investments at the time of purchase. Currently, all of the Company’s investments are classified as available-for-sale in accordance with ASC Topic 320, Investments – Debt Securities (“ASC 320”). The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Investments are classified as long-term assets on the consolidated balance sheets if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income or loss. Realized gains and losses, interest income earned on the Company’s cash, cash equivalents and investments, and amortization or accretion of discounts and premiums on investments are included within other income (expense) on the accompanying consolidated statements of operations and other comprehensive loss. Available-for-sale debt securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported within equity as accumulated other comprehensive income (loss) on the accompanying consolidated statements of stockholder’s equity. The Company did no t record any such impairments during the years ended December 31, 2023 and 2022. Concentration of credit risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, testing, validation and supply services, including production, research and development and clinical activities. The Company’s future revenue as well as research and development programs could be adversely affected by a significant supply interruption by one or more of its contract manufacturers. Leases At inception of a contract, the Company determines whether an arrangement is or contains a lease. For all leases, the Company determines the classification as either operating or financing. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in our consolidated balance sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. If a lease does not provide information to determine an implicit interest rate, the Company uses its incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and non-lease components, are generally accounted for together as a single lease component. The Company has elected to apply the practical short-term expedient to leases with a lease term of 12 months or less, which does not subject the leases to capitalization. Property and equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in gain or loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred . Impairment of long-lived assets Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets. Deferred offering costs The Company capitalizes certain legal, audit, accounting and other third-party fees that are directly associated with an in-process capital financing effort as deferred offering costs until such financing is consummated. After consummation of the financing, these costs are recorded as a reduction of additional paid-in capital generated as a result of the financing. Should the financing be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the accompanying consolidated statements of operations and other comprehensive loss. The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying consolidated statements of operations and other comprehensive loss. Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Coalition for Epidemic Preparedness (“CEPI”) grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID- 19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in early 2022, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. Cash payments received in advance under the CEPI Funding Agreement were restricted as to their use until expenditures contemplated in the funding agreement were incurred. As funds were received they were included within restricted cash offset by a corresponding short-term accrued liability. The Company recognized payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant was intended to reimburse were incurred. Research and development Research and development expenses include employee related costs, consulting, contract research, depreciation, rent, stock-based compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 16). These agreements are generally cancelable by either party, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs Patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. The Company classifies stock-based compensation expense in its consolidated statements of operations and other comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to the Company's IPO in November 2021, there was no public market for the Company’s common stock and the estimated fair value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments and estimates inherent in the determination of the fair value of the Company’s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred securities, the superior rights and preferences of securities senior to the common securities at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on the date of grant based on the fair value of the Company’s common stock on that same date. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model (“Black-Scholes”), which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate and expected dividends. The Company, both prior to and after the IPO in November 2021, lacks sufficient company-specific historical and implied volatility information for its stock, and therefore estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The conditions present in the Company's grants contain both performance and market conditions. The effect of each market condition is reflected in the grant-date fair value and the performance-based options are recognized considering the probability of satisfying the performance and market conditions. The Company has used a Monte Carlo Simulation Model to calculate the fair value of the grant considering the market condition (the 25% higher value after the IPO condition). The performance condition was determined to not be probable at the time of the grant date, and the recognition of compensation cost was deferred until the IPO was consummated in November 2021. The recognition of expense for the portion of the grant-date fair value assigned to the market condition has been recognized as expense according to the derived service period in the valuation model. Income taxes The Company accounts for income taxes according to the ASC 740, Income Taxes (“ASC 740”) using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax positions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net loss per share Basic earnings per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive. For purpose of this calculation, outstanding options, unvested restricted stock and warrants are considered potential dilutive common stock and are excluded from the computation of net loss per share if their effect is anti-dilutive. Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, as long as the Company remains an EGC, it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs. Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018- 11provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be smaller reporting companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company did not enter into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Valuation allowance increase	$ 12,200,000	$ 15,000,000.0
Effective Income Tax Rate Continuing Operations	0.00%	0.00%
Income Tax Examination Penalties And Interest Accrued	$ 100,000	$ 200,000
Tax liabilities reversed due to late returns for tax year 2016 and 2017	$ 600,000
Advanced manufacturing investment tax credit rate	25.00%
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 178,800,000	$ 175,700,000
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 31,200,000

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	December 31, 2023 2022 Accrued compensation $ 1,558 $ 2,568 Accrued external research and development 1,202 6,904 Accrued professional fees and other 560 1,722 Accrued interest 21 176 $ 3,341 $ 11,370

Benefit Plans	12 Months Ended
Benefit Plans	Dec. 31, 2023
Benefit Plans [Abstract]
Benefit Plans	15. Benefit Plans In March 2018, the Company established a defined contribution savings plan under Section 401(k) of the Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches employee contributions to the Plan at 100 % up to 4 % of the employee’s base salary. During the years ended December 31, 2023 and 2022, the Company contributed $ 0.5 million and $ 0.4 million to employees’ 401(k) accounts. The Company offers its Ireland-based employees a Personal Retirement Savings Account (“PRSA”) that allows participants to defer a portion of their annual compensation. The Company provides contributions equal to 5 % of each participant’s annual salary. During the years ended December 31, 2023 and 2022, the Company contributed less than $ 0.1 million per year to the PRSA accounts.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Contractual Obligations The Company enters into agreements with contract research organizations (“CROs”) to conduct clinical trials and preclinical studies and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of December 31, 2023, the Company had no remaining prepayments to CROs or CMOs for activities associated with the conduct of its clinical trials or the production of the Company’s product candidates. Michael J. Fox Foundation Grant On November 3, 2021, the Company was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) in the amount of $ 0.8 million to explore markers for target engagement in individuals immunized with UB-312, an active a -Synuclein immunotherapy. The Company used the funds to oversee sample management, sample preparation (IgG fractions) and distribution, as well as characterize the binding properties of the antibodies against pathological forms of aSyn. Since funding was utilized over a two- year period, as cash was received, the amount expected to be utilized within twelve months was recognized as short-term restricted cash/deposits, with a corresponding short-term accrued liability, which was released as the related expenses were incurred. The Company recognized payments from MJFF as a reduction of research and development expenses, in the same period as the expenses that the grant was intended to reimburse were incurred. The remaining balance of cash received was recognized to long-term restricted cash/deposits, with a corresponding long-term accrued liability. As of December 31, 2023, there was no balance remaining in the accrued liability related to this grant. For the year ended December 31, 2022, the Company recognized $ 0.1 million as a reduction of research and development expenses for amounts reimbursed through the MJFF grant, and did no t recognize any reduction in research and development expenses for the year ended December 31, 2023. Coalition for Epidemic Preparedness Innovations (“CEPI”) Grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI agreed to provide funding of up to $ 9.3 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID- 19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in 2023, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. The Company will also be performing further manufacturing scale-up work to enable readiness for potential commercialization. Under the terms of the agreement with CEPI, if successful, a portion of the released doses of the commercial product will be delivered to the COVID-19 Vaccines Global Access (“COVAX”) consortium for distribution to developing countries at low cost. Cash payments received in advance under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. Funding tranches received are expected to the utilized within twelve months, thus the funds received are reflected within restricted cash with a corresponding short-term accrued liability. The Company recognizes payments from CEPI as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. As of December 31, 2023, there was no remaining balance of restricted cash and short-term accrued liability related to CEPI funds. For the years ended December 31, 2023 and 2022, the Company recognized $ 1.8 million and $ 7.5 million, respectively, as a reduction of research and development expenses for amounts reimbursed through the CEPI grant. Lease Agreements The Company has two operating lease agreements for office and laboratory space. The Company is also required to pay certain operating costs under its leases. In August 2023, the Company renewed its lease for 9,839 square feet of lab and office space with Space Florida in Exploration Park, Florida commencing August 12, 2023. The lease has a initial one-year term with an annual lease obligation of $ 0.5 million, after Lessee credits. Additionally, the lease requires the Company to provide a security deposit in the amount of less than $ 0.1 million. In April 2022, the Company entered into a facility lease agreement for 4,419 square feet of office space in New York, New York. The lease commenced in April 2022 and will expire March 2029 with no option to renew. This lease and its terms were reviewed using the guidance found in ASC 842. Since the lease has a non-cancellable period of one year , and after the first year both the Company and the landlord have the option to early terminate the lease for any or no reason, the Company has elected to apply the short-term expedient, which does not subject the New York lease to capitalization. Rent expense for each of the years ended December 31, 2023 and 2022 amounted to $ 0.6 million and $ 0.5 million, respectively. License Agreements In October 2014, the Company entered into a contribution agreement with UBI, whereby UBI contributed and assigned to the Company assets and granted a non-exclusive license to certain technologies deemed necessary or reasonably useful in the utilization of the licensed intellectual property. In consideration, the Company issued 32,505,306 shares of common stock to UBI. The agreement allowed for exploitation of all diagnostic, prophylactic, and therapeutic uses and indications in humans in the field of neurology. The agreement was amended in August 2019 to provide the Company with exclusivity (except as to UBI) in the field of neurology and the flexibility to pursue indications outside the initial field limitations. In connection with the amendment, the Company agreed to execute an exclusive, worldwide license agreement for any product that is developed by the Company outside the original field. The terms and conditions are to be negotiated in good faith and mutually agreed upon. The Company anticipates that if it is required to enter into an exclusive license agreement, it will be able to negotiate financial terms for the license at prevailing market rates within the pharmaceutical industry. Accordingly, the Company may be required to pay UBI upfront fees, revenue royalties, development milestones, commercial milestones, sublicense fees, and other related fees. Vaxxinity’s COVAXX subsidiary was formed in March 2020 through a transfer of technology from UBI, UBI IP Holdings, and UBI US Holdings, LLC, all related parties of the Company, whereby the Company, pursuant to an April 2020 license agreement, obtained exclusive rights to intellectual property and technology related to the discovery of vaccines, diagnostic assays, and antigens for use against all coronaviruses including, without limitation, SARS, MERS, and COVID-19 in all strains in humans. The license is worldwide, perpetual, exclusive and fully paid-up. There are no future royalty or milestone payment obligations associated with the agreement. The Company has the right to grant sublicenses. The Company considered ASC 805, “Business Combinations” and ASC 730, “Research and Development” in determining how to account for the issuance of common stock. The license agreement is considered to be a common control transfer; however, the related party did not have any basis in the assets licensed, so there was no accounting impact for the Company. In August 2021, Vaxxinity entered into a license agreement (the “Platform License Agreement”) with UBI and certain of its affiliates that expanded intellectual property rights previously licensed under previously issued license agreements with UBI. As part of the agreement, Vaxxinity obtained a worldwide, sublicensable (subject to certain conditions), perpetual, fully paid-up, royalty-free license to research, develop, make, have made, utilize, import, export, market, distribute, offer for sale, sell, have sold, commercialize or otherwise exploit peptide-based vaccines in the field of all human prophylactic and therapeutic uses, except for such vaccines related to human immunodeficiency virus (HIV), herpes simplex virus (HSE) and Immunoglobulin E (IgE). The patents and patent applications licensed under the Platform License Agreement include claims directed to a CpG delivery system, artificial T helper cell epitopes and certain designer peptides and proteins utilized in UB-612. In consideration for the Platform License Agreement, the Company issued to UBI a warrant to purchase Class A common stock (the “UBI Warrant”). The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, Research and Development” (“ASC 730”) in determining how to account for the license agreement acquired and the issuance of the UBI Warrant. The majority of the Voting interests in UBI and in the Company were held by a group of immediate family members, at the time of the transaction, and as such the transaction constitutes a common control transaction, which requires the license to be accounted for at the carrying value in the books of the transferor and the excess of consideration paid over the carrying value as a capital transaction. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has no t accrued any liabilities related to such obligations as of December 31, 2023 or 2022. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of December 31, 2023 and 2022, the Company was not a party to any material legal matters or claims, except as discussed below. In December 2022, the Board became aware of pending litigation filed by the Company’s CEO against a significant stockholder, Ask America, LLC (“Ask America”). The CEO filed the lawsuit in Texas in May 2022 regarding an alleged private agreement between the CEO, the Company’s Chairman, and Ask America, relating to the potential purchase of stock by Ask America in the Company’s November 2021 initial public offering, on behalf of a former director. Ask America asserts that the CEO and Chairman guaranteed a loan by Ask America to fund the former director’s contemplated purchase. The lawsuit seeks a declaration that no enforceable transaction was ever completed or consummated. Although the Company was not a party to the litigation initially, the Board formed a special committee, comprised of independent directors who are being advised by independent legal counsel, to conduct an investigation into the circumstances of the litigation and the purported transaction. The investigation concluded in the first quarter of 2023, and the company implemented certain additional control measures. On November 10, 2023, Ask America LLC (“Ask America”) filed counterclaims against the Company in connection with a pending legal matter between Ask America and the Company’s co-founders. The case is styled Hu v. Ask America LLC, Case No. 3:22-cv- 02432-X, and is pending in the U.S. District Court for the Northern District of Texas. The counterclaims name the Company as a third- party defendant and alleges, among other things, certain violations of the Texas Securities Act and common law fraud. The Company accrues liability for this and other such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. At this time, since the Ask America litigation is at an early stage, the Company does not consider a loss probable and no loss amount is estimable, hence no accrual for loss has been made. Loss Contingency In April 2021, the Company engaged United Biopharma, Inc. (“UBP”) to begin acquiring raw materials for use in the production of GMP grade recombinant protein for UB-612, the Company’s COVID-19 vaccine candidate under an Authorization to Proceed (“ATP”) agreement for $ 3 million of materials. Through August 2021, $ 7.2 million of materials were ordered by UBP, $ 3.0 million of materials were received by UBP and paid for with a $ 3.0 million advance payment from the Company. The Company has recognized $ 3.0 million in expense for these materials purchases authorized under the ATP. When the Company asked to pause further manufacture of protein upon rejection of the Emergency Use Authorization application by Taiwan in August 2021, UBP requested that its suppliers cancel the remaining $ 4.2 million in orders for which it had not taken possession of the materials. In the fourth quarter of 2022, the Company learned that most of the suppliers refused to cancel the orders, although some agreed to seek other buyers for the materials. For these orders, management has not concluded that a loss for the Company is probable, or that one amount of loss is a better estimate than any other amount, since UBP were not originally authorized by the ATP and UBP’s suppliers may be able to dispose of some amount to other buyers. Hence, an expense has no t been recognized for them. There is no claim against the Company by UBP related to these orders, no settlement or other agreement has been reached between the Company and UBP or, to the Company’s knowledge, between UBP and its suppliers. Therefore, the range of the potential loss is still $ 0 to $ 4.2 million.

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	$ 2,316	$ 5,551
Research and development	35,899	47,627
General and administrative	22,386	28,352
Other expense	1,351	757
UBI IP [Member] \| Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	0	237
Amounts due	414	414
Accrued expenses	0	0
Accounts payable	10,575	12,772
Current portion of note payable	1,500	1,113
Note payable	3,735	3,112
Accrued interest payable	0	73
Research and development	568	4,172
General and administrative	2,725	0
Other expense	$ 248	$ 73

Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Defined Contribution Plan Disclosure [Line Items]
Company matches employee contributions to the Plan at 100% up to 4%	100.00%
Company contributions	$ 0.5	$ 0.4
Maximum percentage of employee's base salary employer matches 100%	4.00%
Foreign Plan [Member] \| Personal Retirement Savings Account [Member]
Defined Contribution Plan Disclosure [Line Items]
Company matches employee contributions to the Plan at 100% up to 4%	5.00%
Company contributions	$ 0.1	$ 0.1

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Mar. 25, 2024	Jun. 30, 2023
Document Type	10-K
Document Annual Report	true
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-41058
Entity Registrant Name	VAXXINITY, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-2083865
Entity Address, Address Line One	505 Odyssey Way
Entity Address, City or Town	Merritt Island
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32953
City Area Code	254
Local Phone Number	244-5739
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Fin Stmt Error Correction Flag	false
Entity Shell Company	false
Entity Public Float				$ 155.6
Document Fiscal Year Focus	2023
Documents Incorporated by Reference	Portions of the following document are incorporated by reference in Part III of this Report: the registrant’s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders. We currently anticipate that our definitive proxy statement will be filed with the SEC no later than 120 days after December 31, 2023, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended.
Auditor Name	FORVIS, LLP	ArmaninoLLP
Auditor Firm ID	686	32
Auditor Location	NY	San Ramon, California
Entity Central Index Key	0001851657
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Class A Common Stock [Member]
Entity Common Stock, Shares Outstanding			112,873,552
Common Class B [Member]
Entity Common Stock, Shares Outstanding			13,874,132

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Restricted cash	$ 105,000	$ 1,095,000
Lessee, Lease, Description [Line Items]
Impairment charges	0	$ 0
Funding amount provided	$ 9,300,000

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	112,872,672	112,182,750
Common stock, shares outstanding	112,872,672	112,182,750
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,874,132	13,874,132
Common stock, shares outstanding	13,874,132	13,874,132

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets [Line Items]
Unamortized Portion Insurance Fee	$ 1,200,000	$ 1,600,000

Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 35,899	$ 47,627
General and administrative	22,386	28,352
Total operating expenses	58,285	75,979
Loss from operations	(58,285)	(75,979)
Other (income) expense:
Interest and other expense	696	514
Interest and other income	(2,090)	(1,259)
(Gain) loss on foreign currency translation, net	43	(12)
Other (income)	(1,351)	(757)
Loss before income taxes	(56,934)	(75,222)
Net loss	$ (56,934)	$ (75,222)
Net loss per share, basic	$ (0.45)	$ (0.60)
Net loss per share, diluted	$ (0.45)	$ (0.60)
Weighted average common shares outstanding, basic	126,508,917	125,939,050
Weighted average common shares outstanding, diluted	126,508,917	125,939,050
Other comprehensive loss:
Unrealized loss (gain) on investments	$ (205)	$ 197
Other comprehensive loss (income)	(205)	197
Comprehensive loss	$ (56,729)	$ (75,419)

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Long-Term Liabilities [Abstract]
Accrued tax provision	$ 35	$ 236
Total	$ 35	$ 236

Subsequent Events (Narrative) (Details) - $ / shares	Mar. 08, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Options outstanding		21,923,762	20,416,760
Subsequent Event [Member] \| Continuing Employees And Officers [Member]
Subsequent Event [Line Items]
Options outstanding	10,105,140
Share price	$ 0.70

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2023
Property and Equipment, Net [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Depreciation expense for the years ended December 31, 2023 and 2022 was $ 2.2 million and $ 1.7 million, respectively. December 31, 2023 2022 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 3,649 3,146 Leasehold improvements 576 403 Software 426 415 Facilities, furniture and fixtures 99 37 Vehicles 87 87 Construction in progress 128 65 Total property and equipment 16,948 16,136 Less: accumulated depreciation (5,867) (3,624) $ 11,081 $ 12,512

Notes payable (Carrying Value) (Details) - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Note, 2025 [Member]
Debt Instrument [Line Items]
Principal	$ 10,011	$ 10,455
Unamortized debt issuance cost	(78)	(131)
Total	9,933	10,324
Less: current portion	(406)	(391)
Note payable, net of current portion and debt issuance cost	9,527	9,933
Promissory Note with Related Party [Member]
Debt Instrument [Line Items]
Less: current portion	(472)
Note payable, net of current portion and debt issuance cost	1,652
Promissory 2022 Note [Member]
Debt Instrument [Line Items]
Principal	3,112	4,225
Less: current portion	(1,029)	(1,113)
Note payable, net of current portion and debt issuance cost	2,083	$ 3,112
Promissory 2023 Note [Member]
Debt Instrument [Line Items]
Principal	2,124
Less: current portion	(472)
Note payable, net of current portion and debt issuance cost	$ 1,652

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	24,051,782	22,644,780
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	200,000	300,000
Options Issued And Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	21,923,762	20,416,760
Warrants Issued And Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,928,020	1,928,020

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2023
Common Stock [Abstract]
Common Stock	10. Common Stock Vaxxinity’s Amended and Restated Certificate of Incorporation dated November 15, 2021 authorized 1,100,000,000 shares of common stock with a par value of $ 0.0001 per share, of which 1,000,000,000 shares have been designated as Class A common stock and 100,000,000 shares have been designated as Class B common stock. Holders of Class A common stock and Class B common stock have identical rights, except with respect to voting and conversion. Except as otherwise expressly provided in Vaxxinity’s Amended and Restated Certificate of Incorporation or Bylaws, or required by applicable law, holders of Class A common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders and holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of stockholders, except (i) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation that alter or change the powers, preferences or special rights of a class of capital stock in a manner that affects its holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are entitled to receive, ratably, dividends as may be declared by Vaxxinity’s board of directors out of funds legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, dividend, and liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of Vaxxinity’s preferred stock, if any. The Company has reserved shares of common stock for issuance for the following purposes: December 31, 2023 2022 Options and RSUs issued and outstanding 22,123,762 20,716,760 Options available for future grants 6,266,663 6,064,003 Warrants issued and outstanding 1,928,020 1,928,020 30,318,445 28,708,783

Equity Incentive Plan (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Equity Incentive Plan [Abstract]
Number of Stock Options Outstanding, Balance at December 31, 2022	20,416,760
Number of Stock Options Outstanding, Granted	4,573,829
Number of Stock Options Outstanding, Exercised	(689,922)
Number of Stock Options Outstanding, Forfeited	(2,376,905)
Number of Stock Options Outstanding, Balance at December 31, 2023	21,923,762	20,416,760
Number of Stock Options Outstanding, Options vested and exercisable at December 31, 2023	16,452,984
Weighted Price Per Share, Balance at December 31, 2022	$ 5.07
Weighted Price Per Share, Granted	2.02
Weighted Price Per Share, Exercised	0.66
Weighted Price Per Share, Forfeited	(6.55)
Weighted Price Per Share, Balance at December 31, 2023	4.42	$ 5.07
Weighted Price Per Share, Options vested and exercisable at December 31, 2023	$ 4.37
Weighted Contractual Term (years), Balance at December 31	6 years	6 years 9 months 18 days
Weighted Contractual Term (years), Options vested and exercisable at December 31, 2023	5 years 7 months 6 days
Aggregate Intrinsic Value, Balance at December 31	$ 3,158	$ 7,166
Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2023	$ 3,155

Income Taxes (Schedule of Loss Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Domestic entities	$ (54,850)	$ (69,745)
Entities outside the U.S.	(2,084)	(5,477)
Loss before income taxes	$ (56,934)	$ (75,222)

Short-Term Investments (Tables)	12 Months Ended
Short-Term Investments (Tables)	Dec. 31, 2023
Short Term Investments [Abstract]
Short-Term Investments	As of December 31, 2023 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 25,456 $ 8 $ 25,464 Total $ 25,456 $ 8 $ 25,464 As of December 31, 2022 Amortized Cost Unrealized Gains (Losses), Net Recorded Basis U.S. Treasury Securities $ 53,549 $ (197) $ 53,352 Total $ 53,549 $ (197) $ 53,352

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	December 31, 2023 2022 Consolidated balance sheet Assets Prepaid expenses and other current assets $ — $ 237 Amounts due from related parties 414 414 Liabilities Accrued expenses — — Amounts due to related parties 10,575 12,772 Current portion of note payable 1,500 1,113 Note payable 3,735 3,112 Accrued interest payable $ — $ 73 Years Ended December 31, 2023 2022 Operating expenses Research and development Services provided by related parties $ 568 $ 4,172 General and administrative Services provided by related parties 2,725 — Other expense Related party interest expense $ 248 $ 73

Accrued Expenses and Other Current Liabilities	12 Months Ended
Accrued Expenses and Other Current Liabilities	Dec. 31, 2023
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2023 2022 Accrued compensation $ 1,558 $ 2,568 Accrued external research and development 1,202 6,904 Accrued professional fees and other 560 1,722 Accrued interest 21 176 $ 3,341 $ 11,370

Other Long-Term Liabilities	12 Months Ended
Other Long-Term Liabilities	Dec. 31, 2023
Other Long-Term Liabilities [Abstract]
Other Long-Term Liabilities	8. Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): As of December 31, 2023 and 2022, less than $ 0.1 million and $ 0.2 million of the accrued tax provision relates to penalties and interest the Company may be subject to on transfer pricing related exposures for its foreign subsidiaries. During 2023, statute of limitations expirations enabled the Company to write off approximately $ 0.2 million of accrued penalties and interest. The Company has accrued for the remaining exposures until the statute of limitations expires and it is appropriate to write them off. December 31, 2023 2022 Accrued tax provision $ 35 $ 236 $ 35 $ 236

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions The Company has related party arrangements with UBI and a number of its affiliated companies listed namely, United Biomedical, Inc., Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, Inc (“UBP”), and UBI IP Holding (“UBI-IP”). As of December 31, 2023, UBI and its affiliated companies owned 44 % of the Company’s stock. The majority of the voting interests in both UBI and the Company were held by a group of immediate family members, and as such the entities are under common control. These related parties are governed by various Master Services Agreements (“MSA”) detailed below. UBI MSA - UBI provides research, development and clinical functions to the Company. There is also a purchase arrangement with UBI for the production and shipment of the Company’s diagnostic test kits. UBIA MSA - UBI-Asia for manufacturing, quality control, testing, validation, and supply services. UBP MSA - United BioPharma, Inc. provides the Company with manufacturing, testing, and validation. COVID MSA (“COVID MSA”) - COVID MSA provides that UBI acts as COVAXX’s agent with respect to matters relating the Company’s COVID-19 program and provides research, development, manufacturing, and back office administrative services to the Company. COVID-19 Relief MSA - A four-company MSA with UBI, UBI-Asia and UBP. The Company is an exclusive licensee of technologies related to diagnostics, vaccines, and therapies for COVID-19. The MSA established the terms under which UBI-Asia provides research, development, testing, and manufacturing services to the Company and UBP provides contract development and manufacturing services to the Company. In August 2021, Vaxxinity entered into a license agreement with UBI and certain of its affiliates (collectively, the “Licensors”) that expanded intellectual property rights previously licensed under the Original UBI Licenses in exchange for a warrant to purchase 1,928,020 shares of Vaxxinity Class A common stock. The UBI Warrant is exercisable at an exercise price of $ 12.45 per share (subject to adjustment pursuant thereto), is not subject to vesting, and has a term of five years (see Note 14). The Company also considers Destination Systems, its travel and logistics firm, a related party since its Chief Executive Officer, Landon Ogilvie, is on the Company’s board of directors. Total related party operating activity, including the activity described above is as follows (in thousands): December 31, 2023 2022 Consolidated balance sheet Assets Prepaid expenses and other current assets $ — $ 237 Amounts due from related parties 414 414 Liabilities Accrued expenses — — Amounts due to related parties 10,575 12,772 Current portion of note payable 1,500 1,113 Note payable 3,735 3,112 Accrued interest payable $ — $ 73 Years Ended December 31, 2023 2022 Operating expenses Research and development Services provided by related parties $ 568 $ 4,172 General and administrative Services provided by related parties 2,725 — Other expense Related party interest expense $ 248 $ 73

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Other Long-Term Liabilities (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Other Long-Term Liabilities [Abstract]
Accrued payroll taxes	$ 100,000	$ 100,000
Penalties and interest accrued write off	$ 200,000

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Uncertain tax position liability at the beginning of the year	$ 652	$ 652
Decreases during current period	(617)	0
Uncertain tax position liability at the end of the year	$ 35	$ 652

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Useful life of property and equipment	Estimated Useful Life Airplane 15 years Facilities 5 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Leasehold improvements Shorter of the useful life of improvement or the remaining lease term

Short Term Investments (Details) - USD ($)	12 Months Ended
Short Term Investments (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash And Cash Equivalents [Line Items]
Amortized Cost	$ 25,456,000	$ 53,549,000
Unrealized Gains (Losses), Net	8,000	(197,000)
Recorded Basis	25,464,000	53,352,000
U S Treasury Securities [Member]
Cash And Cash Equivalents [Line Items]
Amortized Cost	25,456,000	53,549,000
Unrealized Gains (Losses), Net	8,000	(197,000)
Recorded Basis	$ 25,464,000	$ 53,352,000

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Loss Before Income Taxes	Years Ended December 31, Losses before taxes 2023 2022 Domestic entities $ (54,850) $ (69,745) Entities outside the U.S. (2,084) (5,477) $ (56,934) $ (75,222)
Reconciliation of Income Tax Percent	Years Ended December 31, 2023 2022 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 2.29 % (1.17) % Stock compensation (1.08) % (0.68) % Foreign rate differential (0.31) % (0.59) % Uncertain tax positions 0.00 % 0.00 % Plane expense (1.15) % 0.00 % Other 0.67 % 1.41 % Change in valuation allowance (21.42) % ( 19.98 ) % Provision for income taxes 0.00 % 0.00 %
Schedule of Deferred Tax Assets	As of December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 42,170 $ 39,184 Section 174 costs 15,631 7,424 Stock compensation 3,385 2,090 Other 225 559 Total deferred tax assets 61,411 49,257 Less: valuation allowance (61,369) (49,173) Net deferred tax assets $ 42 $ 84 Deferred tax liabilities: Depreciation $ (42) $ (84) Net deferred tax liabilities (42) (84) Net deferred income taxes $ — $ —
Schedule of Unrecognized Tax Benefits	Years Ended December 31, 2023 2022 Uncertain tax position liability at the beginning of the year $ 652 $ 652 Decreases during current period (617) — Uncertain tax position liability at the end of the year $ 35 $ 652

Nature of the Business (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Nature of Business Disclosures [Line Items]
Cash and cash equivalents	$ 4,931	$ 33,475
Net Income Loss	(56,934)	(75,222)
Accumulated deficit	(361,637)	(304,703)
Net Cash Provided By Used In Operating Activities	(57,238)	(55,928)
Short Term Investments	$ 25,464	$ 53,352

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2023
Notes Payable [Abstract]
Notes Payable	9. Notes Payable Note Payable—Airplane In connection with the acquisition of an airplane, the Company entered into a note payable agreement (the “2025 Note”) in June 2020 for $ 11.5 million, with an annual interest rate of 3.4 % and a maturity date of June 9, 2025 . Principal and interest payments are payable monthly in the amount of $ 0.1 million with a final payment of $ 9.4 million at maturity. The 2025 Note is guaranteed by the co-founders of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 million, which are being amortized over the term of the loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of December 31, 2023, the remaining principal payments for the 2025 Note, are as follows (in thousands): Interest expense associated with the 2025 Note was $ 0.4 million and $ 0.4 million for the years ended December 31, 2023 and 2022, respectively. 2022 Promissory Note with Related Party In October 2022, the Company entered into a related party unsecured promissory note (the “2022 Promissory Note”) with UBI for $ 4.2 million. The 2022 Promissory Note accrues interest at 7.0 % per annum and is due October 1, 2026. The 2022 Promissory Note was issued to satisfy accounts payable to UBI totaling $ 4.2 million. Interest expense associated with the 2022 Promissory Note was $ 0.2 million and less than $ 0.1 million for the years ended December 31, 2023 and 2022, respectively. The carrying value of the 2022 Promissory Note is as follows (in thousands): As of December 31, 2023, the remaining principal payments for the 2022 Promissory Note, are as follows (in thousands): 2023 Promissory Note with Related Party In December 2023, the Company entered into a related party unsecured promissory note (the “2023 Promissory Note”) with UBI for $ 2.2 million. The 2023 Promissory Note accrues interest at 9.25 % per annum and is due November 1, 2027 . The 2023 Promissory Note was issued to satisfy accounts payable to UBI totaling $ 2.2 million. During the year ended December 31, 2023 the Company incurred less than $ 0.1 million in interest expense related to the 2023 Promissory Note. The carrying value of the 2023 Promissory Note is as follows (in thousands): As of December 31, 2023, the remaining principal payments for the 2023 Promissory Note, are as follows (in thousands): December 31, 2023 2022 Principal $ 10,011 $ 10,455 Unamortized debt issuance cost (78) (131) Carrying amount 9,933 10,324 Less: current portion (406) (391) Note payable, net of current portion and debt issuance cost $ 9,527 $ 9,933 Amount 2024 $ 458 2025 9,553 $ 10,011 December 31, 2023 2022 Principal $ 3,112 $ 4,225 Less: current portion (1,029) (1,113) Note payable, net of current portion and debt issuance cost $ 2,083 $ 3,112 Amount 2024 1,029 2025 1,103 2026 980 $ 3,112 December 31, 2023 Principal $ 2,124 Less: current portion (472) Note payable, net of current portion $ 1,652 Amount 2024 472 2025 517 2026 567 2027 568 $ 2,124